Benjamin Koopmansch
Overview
Explore the profile of Benjamin Koopmansch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nokin M, Darbo E, Richard E, San Jose S, de Hita S, Prouzet-Mauleon V, et al.
Cell Rep Med
. 2024 Aug;
5(8):101663.
PMID: 39094577
The current targeted therapy for BRAF-mutant lung cancer consists of a dual blockade of RAF/MEK kinases often combining dabrafenib/trametinib (D/T). This regimen extends survival when compared to single-agent treatments, but...
2.
Crake R, Gasmi I, Dehaye J, Lardinois F, Peiffer R, Maloujahmoum N, et al.
Cells
. 2023 Jul;
12(10).
PMID: 37408249
Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with poor prognosis. Gemcitabine is the first-line therapy for PDAC, but gemcitabine resistance is a major impediment to achieving satisfactory clinical outcomes....
3.
Bellier J, Nokin M, Caprasse M, Tiamiou A, Blomme A, Scheijen J, et al.
Cell Rep
. 2020 Feb;
30(5):1400-1416.e6.
PMID: 32023458
The use of cetuximab anti-epidermal growth factor receptor (anti-EGFR) antibodies has opened the era of targeted and personalized therapy in colorectal cancer (CRC). Poor response rates have been unequivocally shown...
4.
Herfs M, Roncarati P, Koopmansch B, Peulen O, Bruyere D, Lebeau A, et al.
Br J Cancer
. 2018 Apr;
118(10):1302-1312.
PMID: 29700411
Background: Primary adenocarcinoma of the anal canal is a rare and aggressive gastrointestinal disease with unclear pathogenesis. Because of its rarity, no clear clinical practice guideline has been defined and...
5.
Costanza B, Turtoi A, Bellahcene A, Hirano T, Peulen O, Blomme A, et al.
Oncotarget
. 2018 Mar;
9(12):10665-10680.
PMID: 29535834
The identification of diagnostic and prognostic biomarkers from early lesions, measurable in liquid biopsies remains a major challenge, particularly in oncology. Fresh human material of high quality is required for...
6.
Lovinfosse P, Polus M, Van Daele D, Martinive P, Daenen F, Hatt M, et al.
Eur J Nucl Med Mol Imaging
. 2017 Oct;
45(3):365-375.
PMID: 29046927
Purpose: The aim of this study was to investigate the prognostic value of baseline F-FDG PET/CT textural analysis in locally-advanced rectal cancer (LARC). Methods: Eighty-six patients with LARC underwent F-FDG...
7.
Lovinfosse P, Koopmansch B, Lambert F, Jodogne S, Kustermans G, Hatt M, et al.
Br J Radiol
. 2016 May;
89(1063):20160212.
PMID: 27146067
Objective: Treating metastatic colorectal cancer with anti-EGFR monoclonal antibodies is recommended only for patients whose tumour does not harbour mutations of KRAS or NRAS. The aim of this study was...
8.
Koopmansch B, Berx G, Foidart J, Gilles C, Winkler R
Biochem Biophys Res Commun
. 2013 Feb;
431(4):652-7.
PMID: 23376074
E-cadherin expression is repressed by ZEB2/SIP1 while it is induced by KLF4. Independent data from the literature indicate that these two transcription factors could bind close to each other in...
9.
Nolens G, Pignon J, Koopmansch B, Elmoualij B, Zorzi W, De Pauw E, et al.
Breast Cancer Res
. 2009 Nov;
11(6):R83.
PMID: 19906305
Introduction: Activator protein-2 (AP-2) alpha and AP-2gamma transcription factors contribute to ERBB2 gene overexpression in breast cancer. In order to understand the mechanism by which the ERBB2 gene is overexpressed...
10.
Pignon J, Koopmansch B, Nolens G, Delacroix L, Waltregny D, Winkler R
Cancer Res
. 2009 Mar;
69(7):2941-9.
PMID: 19318561
EGFR or ERBB2 contributes to prostate cancer (PCa) progression by activating the androgen receptor (AR) in hormone-poor conditions. Here, we investigated the mechanisms by which androgens regulate EGFR and ERBB2...